 Home > Medical News > Medicines Company News > China National Institute of Biological Sciences of Sinopharm Group's recombinant new coronavirus vaccine approved for clinical trials

China National Institute of Biological Sciences of Sinopharm Group's recombinant new coronavirus vaccine approved for clinical trials

 Last Update: 2021-05-02
 Source: Internet
 Author: User

Tags

crispr clinical trial

protein function body

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 9, 2021, the recombinant new coronavirus vaccine of the China National Institute of Biological Research of Sinopharm Group obtained the clinical trial approval from the National Medical Products Administration.

The recombinant new coronavirus vaccine is based on the natural structural characteristics of the new coronavirus spike protein (S protein) receptor binding region (RBD), and uses structural biology and computational biology to independently design and develop, and uses genetic engineering technology to construct engineered cell lines and recombinant expression Antigen protein, clear target, strong pertinence.

China Biotech stated that the genetic recombinant protein vaccine has a mature technology route and is suitable for large-scale production.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.